Newsletter | September 1, 2026

09.01.26 -- Shelf Stable Bioprinted Human Tissue Models: A 2026 Nucleate Boston Activator Cohort Interview With Carlos Ezio, CEO, Criocore

SPONSOR

 

 

Join us September 9, 2026, at 10 a.m. ET for Inside the Organoid Services Ecosystem for Drug Discovery. Explore how organoids and other NAMs are advancing drug discovery and translational research, including insights from the NIH Standardized Organoid Modeling Initiative. Discover opportunities, challenges, and practical considerations for scaling organoid technologies and integrating standardized platforms into biopharmaceutical development workflows. Register online today.

FEATURED EDITORIAL

Shelf Stable Bioprinted Human Tissue Models: A 2026 Nucleate Boston Activator Cohort Interview With Carlos Ezio, CEO, Criocore

By Ray Dogum, Chief Editor, Drug Discovery Online

Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development. 

 

DDW 2026 Signaled The Next Era Of Competitive Landscape In IBD

By Gaja Gasiorek and Usman Shabbir, Lifescience Dynamics

At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

Strategic Synthesis Of ASGCT And ASCO 2026

By Johnathon Anderson, Ph.D.

The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.

INDUSTRY INSIGHTS

 

Accelerating Small Molecule Protein Degrader Development

White Paper | Curia

High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification and more.

 

Diagnose Absorption Risks To Improve Preclinical And Clinical Outcomes

Q&A | Lonza

Physiologically based pharmacokinetic modeling is a powerful tool for clinical trial design that can be leveraged alongside early development experiments to reduce costs and accelerate timelines.

 

Ushering In A New Era Of Human-Relevant Drug Discovery

Article | Emulate

With most drug candidates failing before approval, researchers need better ways to predict human responses. Delve into how advances in human-relevant modeling are helping improve decisions.

 

Drug Discovery Beyond Rule Of Five: ECCS Class 3 And 4 Strategies

Webinar | X-Chem

Gain practical guidance for advancing bRo5 candidates through improved permeability and metabolic stability with insights on ECCS classes 3 and 4, optimized in vitro tools, and design principles.

 

Media Selection For In Vitro Testing Of Poorly Soluble Drugs

Q&A | Lonza

Principle scientist Deanna Mudie Ph.D. covers the design of dissolution media to support biopredictive dissolution testing and how the properties of a drug and formulation affect performance.

SOLUTIONS

Services For Advancing mRNA-LNPs From Bench To Clinic

Cytiva

Smarter Analytics For Smarter Cell And Gene Therapies With Digital PCR

QIAGEN